ING117175: a Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir or Efavirenz Each Administered With Two NRTIs in HIV-1-infected Antiretroviral Therapy-naive Adults Starting Treatment for Rifampicin-sensitive Tuberculosis

Trial Profile

ING117175: a Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir or Efavirenz Each Administered With Two NRTIs in HIV-1-infected Antiretroviral Therapy-naive Adults Starting Treatment for Rifampicin-sensitive Tuberculosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 May 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Efavirenz; Nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 May 2017 Planned End Date changed from 1 Dec 2019 to 31 Dec 2019.
    • 08 May 2017 Planned primary completion date changed from 1 Dec 2017 to 30 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top